World Health Organization Raises Warning Over Acute Shortage of Obesity Injections
Fewer than a tenth of people eligible to benefit from GLP-1 drugs such as Wegovy can access them, caution the WHO as it issues its initial recommendations on the drugs.
With more than one billion individuals worldwide now classified as obese, it is urging broader and more equitable availability to these injectable treatments.
According to estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a lifelong illness that can be treated with holistic and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to broad availability to the treatments that can help people shift considerable body mass, notes the body.
Skinny Jab Supply Crisis
Despite the current best projected outlook, the supply of these medications could only cover around 100 million people – under 10% of the global need, according to the health organization.
The guideline urges governments and firms to widen availability, via strategies like licensing agreements.
The intellectual property rights on a key compound – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
How Weight-Loss Jabs Work
The injections replicate a body's own hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people eat less.
Individuals typically see weight reduction within a few weeks of beginning the weekly injections.
Research points to people may put most of the weight back on after a year of discontinuing the drug, as their usual food cravings return.
Being above a healthy weight elevates your likelihood for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.